CD19 and diffuse large B-cell lymphoma: Indeed, anti‐CD19 CAR T‐cell therapies represent a promising advance in the treatment of R/R DLBCL and are now the standard of care treatment for patients whose disease has progressed despite treatment with available standard therapies [42, 43, 44].